The Gastric Residence Time (GRT) of Soctec Capsule After a Standardized Breakfast
Gastric Retention Time of Floating Gastro-Retentive Capsules in Male Healthy Subjects After Breakfast as Measured by Magnetic Resonance Imaging (MRI)
1 other identifier
interventional
15
0 countries
N/A
Brief Summary
The primary objective of the study was to assess the gastric residence time (GRT) of the Soctec capsule after a standardized breakfast. 12 healthy subjects will undergo an initial screening visit. Eligible subjects will undergo the study procedure. The hypothesis is that the GRT of the Soctect Capsule after a standardized breakfast and lunch will be longer compared to literature values reported for a simliar sized capsule.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for early_phase_1 healthy
Started Sep 2014
Shorter than P25 for early_phase_1 healthy
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2014
CompletedFirst Submitted
Initial submission to the registry
January 7, 2015
CompletedFirst Posted
Study publicly available on registry
January 9, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2015
CompletedJanuary 9, 2015
January 1, 2015
1 month
January 7, 2015
January 8, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To assess the gastric residence time (GRT) of the Soctec Capsule after a standardized breakfast.
MRI scnas will be performed every 30 minutes starting after capsule intake for up to 12 hours
Study Arms (1)
Soctec / Capsule
EXPERIMENTALHS intakes one(1) Soctec Capsule after standardized breakfast
Interventions
Eligibility Criteria
You may qualify if:
- Male HS, aged between 18 and 50 years.
- Subjects must be in a good health and have BMI between 19 and 25 kg/m2.
- Subjects must be able to read, understand and sign the written informed consent.
- Subjects must be willing and able to comply with study requirements.
You may not qualify if:
- History of gastrointestinal, cardiorespiratory (including arterial hypertension), hematologic, renal, atopic, alimentary or psychiatric disorder, panic attacks, diabetes, drug or alcohol abuse.
- Subjects with a history of HIV, hepatitis B or hepatitis C.
- Requiring medication that might alter gut function, including anticholinergics, calcium channel blockers, beta blockers, laxatives, prokinetics, proton-pump inhibitors and non-steroidal anti-inflammatory drugs.
- Prior abdominal surgery other than uncomplicated appendectomy or hernia repair.
- Subject with claustrophobia (fear of small spaces).
- Presence of implants, devices or metallic foreign bodies that might interact with the MRI
- Participation in another investigational study where the study drug was received within 90 days prior to the screening visit.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- SkyePharma AGlead
- University of Zurichcollaborator
Study Officials
- STUDY DIRECTOR
Karim Bagate, PhD
SkyePharma AG
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 7, 2015
First Posted
January 9, 2015
Study Start
September 1, 2014
Primary Completion
October 1, 2014
Study Completion
March 1, 2015
Last Updated
January 9, 2015
Record last verified: 2015-01